We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Imaging Biometrics Ltd | LSE:IQAI | London | Ordinary Share | Ordinary Shares |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.825 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.80 | 0.85 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.825 | GBP |
| Date | Time | Source | Headline |
|---|---|---|---|
| 27/5/2025 | 07:00 | UK RNS | Imaging Biometrics Limited Change of Name |
| 22/5/2025 | 14:23 | UK RNS | IQ-AI Limited Result of AGM |
| 02/5/2025 | 13:28 | ALNC |  IN BRIEF: IQ-AI applies for breakthrough therapy designation for GaM |
| 02/5/2025 | 07:29 | UK RNS | IQ-AI Limited Application: FDA Breakthrough Therapy Designation |
| 29/4/2025 | 10:49 | UK RNS | IQ-AI Limited Notice of AGM |
| 25/4/2025 | 13:46 | UK RNS | IQ-AI Limited Publication of Annual Report |
| 11/4/2025 | 15:32 | UK RNS | IQ-AI Limited Promising Preliminary Results of Phase 1 Study |
| 18/3/2025 | 10:38 | UK RNS | IQ-AI Limited Placing to raise £250,000 |
| 03/2/2025 | 19:22 | ALNC | IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis |
| 03/2/2025 | 07:00 | UK RNS | IQ-AI Limited IB Expands Distribution with Blackford |
Imaging Biometrics (IQAI) Share Charts1 Year Imaging Biometrics Chart |
|
1 Month Imaging Biometrics Chart |
Intraday Imaging Biometrics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 07/5/2025 | 12:48 | AI Creating the Standard in Image Quantification - (Medical/Neuro)) | 1,755 |
| 22/2/2024 | 11:52 | Imaging Quantification - Artificial Intelligence | 7,454 |
| 20/2/2024 | 16:35 | Colwyn Bay Free | 24 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 07/5/2025 12:48 by greenlane78 Those who are negative about this company have probably bought shares at a much higher price. However, I see an upside to 1.4 p which is my price target. |
Posted at 02/5/2025 08:26 by kingston78 Today is the turning point foe the share, which is poised to reach 1.4 p in the not too distant future. |
Posted at 16/1/2025 09:11 by soulac1 AI for imagery... That's what Iqai has patent for!AI is giving radiologists crisper images with less noise and better analytics, providing a fuller and truer diagnostic picture to inform treatment decisions earlier in the care pathway when a patient's chances for remission and long-term survivability are higher.Deep-learning algorithms are likewise analyzing x-rays, CT scans, and MRI scans to greater effect, using pattern recognition to help detect malignancies and growths potentially missed by the human eye. Researchers are also pairing AI models with specific targeting compounds to help improve diagnostic accuracy. |
Posted at 15/1/2025 15:03 by m_night10 #TERN next I think for an easy 300-500% pump from here. Multiple large tech companies in the portfolio.Used to trade at 30-50p a share and now just 1.4p with the placing churned. Has AI too. Check out the loading in recent weeks. |
Posted at 29/11/2024 09:13 by howdlep With partner/s discussions well under way, I thought it might be interesting to look at the benefits of direct funding v equity stake:-Funding an FDA Phase 2 trial can be approached through direct funding or by taking a stake in the sponsoring company. Here's how each approach works and their respective advantages and disadvantages: 1. Direct Funding of the Trial This method involves a third party (e.g., an investor, pharmaceutical company, or institution) providing funds specifically for the trial, without acquiring equity in the sponsoring company. Mechanisms: Grants or Donations: The third party provides money explicitly for the trial as a grant or donation. This is common with non-profit organizations or government funding bodies, such as the National Institutes of Health (NIH) or patient advocacy groups. Clinical Trial Agreements (CTAs): A contract is established where the third party agrees to fund the trial in return for access to data, intellectual property (IP), or a share of future revenues if the treatment is commercialized. Venture Philanthropy: A philanthropic organization funds the trial but may expect a financial return (e.g., a share of royalties) if the therapy succeeds. Advantages: Non-dilutive Financing: The sponsoring company retains full control of its equity. Faster Execution: Direct funding agreements can be faster to negotiate than equity investments. Aligned Focus: Funds are restricted to trial-related activities, ensuring resources are used as intended. Disadvantages: Limited Upside for Funders: Funders may not benefit from the broader growth of the sponsoring company. Stringent Conditions: Funders might impose detailed conditions, such as milestone-based payments or data-sharing requirements. Short-Term Commitment: Direct funding may only cover the specific trial, requiring the sponsor to seek additional funds for subsequent phases. 2. Taking a Stake in the Sponsoring Company This approach involves a third party acquiring equity in the company sponsoring the trial, providing funding that the company can allocate toward the trial or other operational needs. Mechanisms: Equity Investment: The third party purchases shares in the sponsoring company, often at a discounted price, as part of a funding round. Convertible Debt: The third party lends money, which converts into equity at a future date or milestone (e.g., trial success). Licensing or Partnership: In addition to acquiring a stake, the third party may secure exclusive rights to commercialize the treatment if it succeeds. Advantages: Broader Financial Support: Equity funding can cover not just the trial but other operational or developmental needs. Incentive Alignment: Funders gain upside potential if the sponsoring company succeeds overall. Strategic Partnerships: The third party may bring additional resources, such as expertise or connections, that benefit the sponsor. Disadvantages: Dilution: Existing shareholders lose equity, reducing their ownership percentage. Complexity: Negotiating equity stakes, especially with valuation and control issues, can be time-consuming. Loss of Control: Significant equity sales might give the third party influence over company decisions. Key Considerations for Sponsors: Risk Tolerance: Direct funding minimizes dilution but could impose strict conditions. Equity sales share risk with the funder but reduce control. Time Horizon: Direct funding is better for short-term, trial-specific needs. Equity stakes can support longer-term company growth. Strategic Goals: If the goal is to establish a long-term partnership (e.g., commercialization assistance), equity investment might be more suitable. Example Scenarios: Direct Funding: A patient advocacy group provides $2 million to fund a Phase 2 trial, with the agreement that the group will receive access to anonymized trial data and a small percentage of future royalties. Equity Stake: A pharmaceutical company invests $5 million in the sponsor, acquiring a 20% stake and securing the right of first refusal for Phase 3 trials and eventual commercialization. Conclusion: The choice between direct funding and taking an equity stake depends on the sponsor's strategic priorities, the third party's goals, and the nature of the trial. A hybrid approach, such as partial funding combined with equity investment, might also be possible to balance the benefits and risks of both options. |
Posted at 06/11/2024 09:51 by ivyhedge I wonder if TB was just guessing where the Labour party taxes were going and banked things before it got worse. They may not have been able to get out at the top but I suspect they still got out at a profit on thier original stake.I am still building my stake in Braveheart as I am happy to hold for the long term and it spreads the risk across several companies and not just this one. But having said that I dont see a problem with this share. I think you have a good chance to double your stake or better at this price. |
Posted at 11/10/2024 11:00 by howdlep which of course means TB has cash to buy shares in IQAI on the open market or a future placing without going over the 30% and triggering a buyout. Clever |
Posted at 11/10/2024 10:33 by howdlep OK so BRH have bought all the IQAI and FAB shares.N.B. TB/FAB already held 25.15% of #BRH. So they both pocket money from the sale of their IQAI shares but hold a combined 25.15% of the enlarged #BRH |
Posted at 10/5/2024 10:31 by festario Time was, that an announcement like that would have propelled the share price from 10p to nearer 15p That is until he decided to rape the share price, and us, for his own greed. As it stands, no one believes a word that comes out via RNS anymore, and today we will probably end up level, or even possibly down. He needs some new sheep to fleece, we don't fall for it any more. |
Posted at 31/1/2024 14:36 by cliffv69 Philip, So if it's business as usual and all above board like you say. Why has the share price almost halved since it's 5p plus spike over the last month? Could it be manipulated by those FAB sales to reduce the share price for them to buy back in cheaper whilst taking a profit? Could it be that shareholders see what I see and that if anything big was going to happen soon, why would TB want to upset the apple cart now? I know you are IQAI's biggest fan and probably hold many shares but think logically for a minute. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
